实用老年医学

实用老年医学 ›› 2024, Vol. 38 ›› Issue (10): 1025-1029.doi: 10.3969/j.issn.1003-9198.2024.10.013

• 临床研究 • 上一篇    下一篇

达格列净对接受冠状动脉介入治疗的伴有射血分数降低的心力衰竭合并2型糖尿病老年病人疗效观察

顾崇怀, 项学军, 郑元喜, 乔锐, 林松   

  1. 246000 安徽省安庆市,安庆市立医院心血管内科(顾崇怀,项学军,郑元喜,乔锐);
    210006 江苏省南京市,南京医科大学附属南京医院心血管内科(林松)
  • 收稿日期:2023-12-11 出版日期:2024-10-20 发布日期:2024-10-22
  • 通讯作者: 林松,Email:linsong19711991@sina.com
  • 基金资助:
    安庆市科技局项目(2021Z2001);安庆市立医院科研项目(2022aqykj11)

Efficacy of dapagliflozin in elderly patients undergoing coronary intervention with type 2 diabetes mellitus and ejection fraction reduced heart failure

GU Chonghuai, XIANG Xuejun, ZHENG Yuanxi, QIAO Rui, LIN Song   

  1. Department of Cardiology, Anqing Municipal Hospital, Anqing 246000, China (GU Chonghuai, XIANG Xuejun, ZHENG Yuanxi, QIAO Rui);
    Department of Cardiology, Nanjing First Hospital of Nanjing Medical University, Nanjing 210006, China(LIN Song)
  • Received:2023-12-11 Online:2024-10-20 Published:2024-10-22
  • Contact: LIN Song, Email:linsong19711991@sina.com

PDF (PC)

215

摘要： 目的 探讨达格列净对行冠状动脉介入治疗(PCI)伴有射血分数降低的心力衰竭(HFrEF)合并T2DM老年病人的临床疗效。 方法 回顾性分析2019年11月至2022年11月在安庆市立医院心血管内科住院并接受PCI治疗合并T2DM和HFrEF的老年冠心病病人80例,按照是否使用达格列净治疗分为达格列净组(n=44)和对照组(n=36),记录并比较2组住院期间及中远期随访期间主要不良心血管事件(MACEs)的发生情况。 结果 2组基线资料比较,差异均无统计学意义(P＞0.05)。随访期间达格列净组总体MACEs事件发生率显著低于对照组(4.54%比19.44%,P=0.036)。Cox回归分析结果显示达格列净的使用为HFrEF病人发生MACEs事件的保护性因素(HR=0.300,95%CI:0.010~0.920)。 结论 达格列净是接受PCI治疗合并T2DM的冠心病病人的保护因素,达格列净可以有效降低冠心病合并T2DM的HFrEF老年病人中远期MACEs事件的发生率。

关键词: 达格列净, 冠心病, 2型糖尿病, 射血分数降低的心力衰竭

Abstract: Objective To investigate the efficacy of dapagliflozin in the elderly patients with heart failure with reduced ejection fraction (HFrEF) complicated with type 2 diabetes mellitus (T2DM) who underwent percutaneous coronary intervention (PCI). Methods The clinical data of 80 elderly patients with coronary heart disease complicated with T2DM and HFrEF who were hospitalized in Department of Cardiovascular Medicine of Anqing Municipal Hospital from November 2019 to November 2022 were retrospectively analyzed.The patients were divided into dapagliflozin group (n=44) and control group (n=36) according to whether they used dapagliflozin or not. The incidence of major adverse cardiovascular events (MACEs) during hospitalization and follow-up period was recorded and analyzed in each group. Results There were no significant differences in the clinical baseline data between the two groups (P>0.05). However, the overall incidence rate of MACEs was significantly lower in dapagliflozin group than that in control group (4.54% vs. 19.44%, P=0.036). Cox regression analysis showed that the use of dapagliflozin was a strong protective factor for MACEs in the elderly patients with HFrEF complicated with T2DM (HR=0.030, 95%CI:0.010-0.921). Conclusions Dapagliflozin is a protective factor in the elderly patients with HFrEF complicated with T2DM undergoing PCI,which could reduce the incidence rate of medium and long-term MACEs.

Key words: dapagliflozin, coronary heart disease, type 2 diabetes mellitus, heart failure with reduced ejection fraction

中图分类号: